The purpose of this paper is to examine the eventual benefits of treatment with calcium channel blockers in post-myocardial infarction, through an overview of main placebo-controlled trials that have been conducted to test this therapeutic in acute coronary syndromes. It appears obvious that the vast majority of these trials was conducted in the pre-reperfusion era and failed to demonstrate a reduction in mortality. To conclude, the superiority of a therapy with calcium antagonists over a placebo in the management of post-myocardial infarction remains unknown. In contrast, adverse effects associated with the prescription of calcium antagonists are well known.
Keywords: calcium channel blockers; essais cliniques; infarctus du myocarde; inhibiteurs calciques; myocardial infarction; randomized trials.
Copyright © 2006 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.